BlackRock’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-2,231,444
| Closed | -$13.1M | – | 5202 |
|
|
2019
Q1 | $13.1M | Buy |
2,231,444
+98,696
| +5% | +$336K | ﹤0.01% | 2975 |
|
|
2018
Q4 | $2.77M | Buy |
2,132,748
+39,581
| +2% | +$68.8K | ﹤0.01% | 3575 |
|
|
2018
Q3 | $7.22M | Sell |
2,093,167
-28,104
| -1% | -$106K | ﹤0.01% | 3377 |
|
|
2018
Q2 | $9.65M | Buy |
2,121,271
+204,171
| +11% | +$813K | ﹤0.01% | 3252 |
|
|
2018
Q1 | $6.33M | Buy |
1,917,100
+49,022
| +3% | +$174K | ﹤0.01% | 3328 |
|
|
2017
Q4 | $7.29M | Buy |
1,868,078
+830,861
| +80% | +$4.53M | ﹤0.01% | 3295 |
|
|
2017
Q3 | $10.7M | Sell |
1,037,217
-39
| -0% | -$384 | ﹤0.01% | 3132 |
|
|
2017
Q2 | $10.1M | Buy |
1,037,256
+139,914
| +16% | +$982K | ﹤0.01% | 3163 |
|
|
2017
Q1 | $6.1M | Buy |
897,342
+892,551
| +18,630% | +$5.16M | ﹤0.01% | 3323 |
|
|
2016
Q4 | $27K | Buy |
4,791
+1,628
| +51% | +$11.5K | ﹤0.01% | 3172 |
|
|
2016
Q3 | $23K | Hold |
3,163
| – | – | ﹤0.01% | 3259 |
|
|
2016
Q2 | $26K | Buy |
3,163
+2,189
| +225% | +$27.3K | ﹤0.01% | 3200 |
|
|
2016
Q1 | $13K | Buy |
974
+513
| +111% | +$5.92K | ﹤0.01% | 3060 |
|
|
2015
Q4 | $9K | Sell |
461
-800
| -63% | -$13.8K | ﹤0.01% | 2962 |
|
|
2015
Q3 | $15K | Buy |
1,261
+1,100
| +683% | +$20.6K | ﹤0.01% | 2567 |
|
|
2015
Q2 | $3K | Hold |
161
| – | – | ﹤0.01% | 3207 |
|
|
2015
Q1 | $3K | Buy |
+161
| New | +$4.2K | ﹤0.01% | 3126 |
|
BlackRock's IMDZ Position: Q2 2019 in Review
BlackRock sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 2,231,444 shares — an estimated $13.1M sold.
BlackRock first reported a position in IMDZ in Q1 2015 and held it in 17 quarters. The position peaked at $13.1M in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- BlackRock reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- BlackRock sold 2,231,444 Immune Design Corp. shares in Q2 2019, an estimated $13.1M.
- BlackRock first reported a position in Immune Design Corp. in Q1 2015 and held it in 17 quarters.
- BlackRock's Immune Design Corp. position peaked at $13.1M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on BlackRock's 13F filing for Q2 2019, filed 13 Aug 2019.